Drug Patents owned by Metuchen Pharms

1. List of Stendra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6656935 METUCHEN PHARMS Aromatic nitrogen-containing 6-membered cyclic compounds
Apr, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7501409 METUCHEN PHARMS Preparations for oral administration
May, 2023

(2 months from now)

Exclusivity Exclusivity Expiration
M Oct 18, 2025

Drugs and Companies using AVANAFIL ingredient

Market Authorisation Date: 27 April, 2012

Treatment: Treatment of erectile dysfunction

Dosage: TABLET;ORAL

How can I launch a generic of STENDRA before it's patent expiration?
More Information on Dosage

STENDRA family patents

9

Japan

6

United States

5

Australia

5

China

3

Korea, Republic of

3

Canada

3

European Union

2

Austria

2

Hong Kong

2

Spain

2

Mexico

2

Hungary

2

Norway

2

New Zealand

1

Brazil

1

Malaysia

1

Luxembourg

1

Germany

1

Israel

1

Argentina

1

South Africa

1

Portugal

1

Belgium

1

Russia

1

Bulgaria

1

Turkey

1

Taiwan, Province of China

1

Denmark

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic